Alphabetically arranged by state, this indispensable annual director to over 21,000 employers offers a variety of pertienent contact, business, and occupational data. - American Library Association, Business Reference and Services Section (BRASS) Completely updated to include the latest industries and employers, this guide includes complete profiles of more than 20,000 employers nationwide featuring: Full company name, address, phone numbers, and website/e-mail addresses Contacts for professional hiring A description of the companys products or services Profiles may also include: Listings of professional positions advertised Other locations Number of employees Internships offered
This basic source for identification of U.S. manufacturers is arranged by product in a large multi-volume set. Includes: Products & services, Company profiles and Catalog file.
Adult growth hormone deficiency (aGHD) is the clinical expression of a reduced GH secretion caused by congenital or acquired diseases affecting the hypothalamus-pituitary axis. Once considered a rare clinical disorder, its prevalence is apparently increasing. Nevertheless, due to the subtle clinical manifestations, aGHD could be still underestimated. Thirty years of experience with recombinant GH (rh-GH) clearly indicate the beneficial effects of replacement therapy with amelioration of metabolic and inflammatory parameters, body composition, endothelial function, quality of life, and reduction of cardiovascular risk. Furthermore, the world of GH and aGHD is rapidly enriching: new information on GH physiology, regarding its metabolic role and pleiotropic activities, is spreading, thus even making inappropriate the same name of “growth hormone”. The definition of “functional” and “partial” aGHD is still unclear and debated, although data about partially impaired GH secretion showed alteration of some metabolic and clinical parameters associated with cardiovascular risk. Current guidelines about GHD diagnosis and treatment have been elaborated, but many questions remain debated. New tests for diagnosis have recently been proposed, and non-conventional indications for diagnosis and treatment deserve further investigations. Controlled trials on the beneficial effects on morbidity and mortality are still lacking and new formulations of GH are under investigation. Several questions are related to the age of affected patients (from transition age to ageing) and no indications are available on how long the therapy should be considered. Other concerns are related to a possible pro-oncogenic effect, especially in patients who develop the deficiency after a removal of a hypothalamic-pituitary tumor. The interrelations with other pituitary axes need further clarification since isolate GHD and multiple pituitary deficiencies may have a different spectrum of manifestation. The aim of this Research Topic is to furnish deeper insight to questions related to aGHD: from molecular pathways involved in the pathophysiology to diagnostic tools and replacement therapy.
It is an exciting time to follow the new developments in the field of biotechnology and its wider applications in the different areas. The whole genomes of over 1000 viruses and over 100 microbes can now be found in Entrez Genome. The genomes represent both completely sequenced organisms and those for which sequencing is still in progress. The three main domains of life - bacteria, archaea, and eukaryota - are represented, as well as many viruses and organelles. The exponential increase of the sequence data lead to the development of the new "Bioinformatics" field in order to attempt making sense, at least biological sense, out of all the new and fast data.It will take also other techniques such as "functional genomics" to link the gap between a specific phenotype or a treatment and a gene sequence. Functional genomics tools are therefore important for the accurate molecular diagnosis/prognosis, target discovery validation needed for drug development and novel targets for antibiotics development. Functional genomics are also important for the confirmation of therapy in pharmacogenomics studies. Biotechnology is in many respects shaping our life and affecting our means of production and the creation of jobs. Progress in the applications of biotechnology depends on a wide base of basic as well as applied sciences. The output of biotechnology has already proved itself in many diverse fields from health tobiomining and from agriculture to enzyme "breeding". It is therefore difficult to follow all of the current as well as the potential applications of biotechnology.The objective of the Biotechnology Annual Review series is to attempt to provide readers with the needed indepth knowledge, by reviewing specific topics in biotechnology in each issue. The philosophy behind this series is to encourage good reviews to make it easier for readers to keep in touch with progress and applications of biotechnology. Reviews on topics related to regulatory affairs, social impact of biotechnology, biodiversity, biosafety, public acceptance and patent issues are also encouraged.
First the Seed spotlights the history of plant breeding and shows how efforts to control the seed have shaped the emergence of the agricultural biotechnology industry. This second edition of a classic work in the political economy of science includes an extensive, new chapter updating the analysis to include the most recent developments in the struggle over the direction of crop genetic engineering. 1988 Cloth, 1990 Paperback, Cambridge University Press Winner of the Theodore Saloutos Award of the Agricultural History Society Winner of the Robert K. Merton Award of the American Sociological Association
The authors have conducted extensive research into the role of business in public life. This book takes a practice-oriented look at corporate citizenship, and uses real, behind the scenes examples from well-known companies to show that for many firms social responsibility is becoming more integrated into corporate strategy.
